Beta Bionics — Third Quarter 2026 Earnings Summary

Beta Bionics reported third-quarter 2026 net sales of $35.5 million, representing a 30% increase from the prior year, driven by an 118% surge in Pharmacy Benefit Plan channel revenue. The company announced FDA clearance for its Mint device, with a full U.S. commercial launch expected in the first quarter of 2027, while withdrawing its 510(k) application for 3D Intelligence to submit revised data in mid-2026. Financial results for the quarter showed a net loss of $24.4 million and adjusted EBITDA of negative $18.9 million, with the company raising approximately $161.3 million through a recent public offering. Full-year 2026 revenue guidance was updated to a range of $124 million to $126 million, reflecting potential revenue deferrals as customers await the Mint launch.